![](/img/cover-not-exists.png)
PCN145 COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
Xin, G., Li, H.C., Peng, C., Wang, N., Ma, X., Xiong, X.M., Ma, A.X.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.269
Date:
May, 2019
File:
PDF, 324 KB
english, 2019